Spots Global Cancer Trial Database for Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib
Official Title: A Phase 2, Single-Arm, Open-Label, Multicenter Study of the Bruton Tyrosine Kinase Inhibitor Zanubrutinib in Patients With CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Study ID: NCT05068440
Interventions
Study Description
Brief Summary: Study consists of a single arm to explore the efficacy and safety of zanubrutinib in participants with CD79B mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Anhui Provincial Cancer Hospital Aka West Branch of Anhui Province Hospital, Hefei, Anhui, China
Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
Fujian Cancer Hospital, Fuzhou, Fujian, China
Sun Yat Sen University Cancer Center, Guangzhou, Guangdong, China
Guangdong Provincial Peoples Hospital Huifu Branch, Guangzhou, Guangdong, China
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China
Hainan Cancer Hospital, Haikou, Hainan, China
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
Henan Cancer Hospital, Zhengzhou, Henan, China
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China
The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
Hunan Cancer Hospital, Changsha, Hunan, China
The First Affiliated Hospital of Nanchang University Branch Donghu, Nanchang, Jiangxi, China
The First Hospital of Jilin University, Changchun, Jilin, China
Liaoning Cancer Hospital and Institute, Shenyang, Liaoning, China
Rui Jin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Shanxi Provincial Cancer Hospital, Taiyuan, Shanxi, China
West China Hospital, Sichuan University, Chengdu, Sichuan, China
Institute of Hematology and Hospital of Blood Disease, Tianjin, Tianjin, China
Yunnan Cancer Hospital, Kunming, Yunnan, China
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Zhejiang University College of Medicine Second Affiliated Hospital, Hangzhou, Zhejiang, China
Taizhou Hospital of Zhejiang, Taizhou, Zhejiang, China
Contact Details
Name: Study Director
Affiliation: BeiGene
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
